EUVIMEDEUVIMED entdecken
Open Access

TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function

Alexander J Dimitri iD, Amy E Baxter iD, Gregory M Chen iD, Caitlin R Hopkins iD, Geoffrey T Rouin, Hua Huang, Weimin Kong, Christopher H Holliday, Volker Wiebking iD, Robert Bartoszek iD, Sydney Drury iD, Katherine Dalton iD und 30 weitere

Science Advances · 15.11.2024 · 10 (46)

DOI: 10.1126/sciadv.adp9371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 15.11.2024. Verfasst von Alexander J Dimitri und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Cell Differentiation, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins, Dioxygenases. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD8 + T cell exhaustion hampers control of cancer and chronic infections and limits chimeric antigen receptor (CAR) T cell efficacy. Targeting TET2 in CAR T cells provides therapeutic benefit; however, TET2’s role in exhausted T cell (T EX ) development is unclear. In chronic lymphocytic choriomeningitis virus (LCMV) infection, TET2 drove conversion from stem cell–like T EX progenitors toward terminally differentiated and effector (T EFF )–like T EX . TET2 also enforced a terminally differentiated state in the early bifurcation between T EFF and T EX , indicating broad roles for TET2 in acquisition of effector biology. To exploit the therapeutic potential of TET2, we developed clinically actionable TET2- targeted CAR T cells by disrupting TET2 via knock-in of a safety switch alongside CAR knock-in at the TRAC locus. TET2 -targeted CAR T cells exhibited restrained terminal exhaustion in vitro and enhanced antitumor responses in vivo. Thus, TET2 regulates fate transitions in T EX differentiation and can be targeted with a safety mechanism in CAR T cells for improved tumor control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell DifferentiationCD8-Positive T-LymphocytesProto-Oncogene ProteinsDioxygenasesDNA-Binding ProteinsReceptors, Chimeric AntigenAnimalsMiceHumansLymphocytic choriomeningitis virusLymphocytic ChoriomeningitisImmunotherapy, Adoptive

Substanzen

Proto-Oncogene ProteinsDioxygenasesDNA-Binding ProteinsReceptors, Chimeric AntigenTet2 protein, mouseTET2 protein, human

Autor:innen und Institutionen

  • Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department for Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Alexander J Dimitri, Amy E Baxter, Gregory M Chen, Caitlin R Hopkins, Volker Wiebking, Robert Bartoszek, Sydney Drury, Katherine Dalton, Josephine R Giles, Alexander T Dils, Roddy O'Connor, Sierra Collins, John K Everett, Kevin Amses, Scott Sherrill-Mix, Aditi Chandra, Naomi Goldman, Julie K Jadlowsky, Regina M Young, Jan Joseph Melenhorst, Shannon L Maude, Bruce L Levine, Noelle V Frey, Shelley L Berger, Stephan A Grupp, Friederike Herbst, Matthew H Porteus, Shannon A Carty, Frederic D Bushman, Evan W Weber, E John Wherry, Martha S Jordan, Joseph A Fraietta

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIA NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Dimitri, A. J., Baxter, A. E., Chen, G. M., Hopkins, C. R., Rouin, G. T., Huang, H., Kong, W., Holliday, C. H., Wiebking, V., Bartoszek, R., Drury, S., Dalton, K., Koucky, O. M., Chen, Z., Giles, J. R., Dils, A. T., Jung, I. Y., O'Connor, R., Collins, S., …, & Fraietta, J. A. (2024). TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function. Science Advances, 10(46). https://doi.org/10.1126/sciadv.adp9371

Vancouver

Dimitri AJ, Baxter AE, Chen GM, Hopkins CR, Rouin GT, Huang H, et al. TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function. Science Advances. 2024;10(46). doi:10.1126/sciadv.adp9371

BibTeX
@article{Dimitri2024,
  author = {Dimitri, Alexander J and Baxter, Amy E and Chen, Gregory M and Hopkins, Caitlin R and Rouin, Geoffrey T and Huang, Hua and Kong, Weimin and Holliday, Christopher H and Wiebking, Volker and Bartoszek, Robert and Drury, Sydney and Dalton, Katherine and Koucky, Owen M and Chen, Zeyu and Giles, Josephine R and Dils, Alexander T and Jung, In-Young and O'Connor, Roddy and Collins, Sierra and Everett, John K and Amses, Kevin and Sherrill-Mix, Scott and Chandra, Aditi and Goldman, Naomi and Vahedi, Golnaz and Jadlowsky, Julie K and Young, Regina M and Melenhorst, Jan Joseph and Maude, Shannon L and Levine, Bruce L and Frey, Noelle V and Berger, Shelley L and Grupp, Stephan A and Porter, David L and Herbst, Friederike and Porteus, Matthew H and Carty, Shannon A and Bushman, Frederic D and Weber, Evan W and Wherry, E John and Jordan, Martha S and Fraietta, Joseph A},
  title = {TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {46},
  doi = {10.1126/sciadv.adp9371}
}
Kostenlos starten →